Rekah Pharmaceutical Industry Management
Management criteria checks 4/4
Rekah Pharmaceutical Industry's CEO is Mordechai Elgrabli, appointed in Apr 2015, has a tenure of 9.58 years. total yearly compensation is ₪1.01M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 15.32% of the company’s shares, worth ₪25.89M. The average tenure of the management team and the board of directors is 8.5 years and 9.6 years respectively.
Key information
Mordechai Elgrabli
Chief executive officer
₪1.0m
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 9.6yrs |
| CEO ownership | 15.3% |
| Management average tenure | 8.5yrs |
| Board average tenure | 9.6yrs |
Recent management updates
Recent updates
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up
Jul 11
Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden
Jul 05Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year
Dec 14Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet
Sep 12Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)
Jul 19Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit
Apr 13We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt
May 12Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today
Apr 09Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?
Mar 12Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Feb 19
Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?
Jan 29Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock
Jan 08How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?
Dec 18Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%
Nov 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₪7m |
| Mar 31 2024 | n/a | n/a | -₪6m |
| Dec 31 2023 | ₪1m | ₪1m | -₪7m |
| Sep 30 2023 | n/a | n/a | -₪8m |
| Jun 30 2023 | n/a | n/a | -₪3m |
| Mar 31 2023 | n/a | n/a | -₪2m |
| Dec 31 2022 | ₪845k | ₪845k | -₪2m |
| Sep 30 2022 | n/a | n/a | ₪4m |
| Jun 30 2022 | n/a | n/a | ₪3m |
| Mar 31 2022 | n/a | n/a | ₪5m |
| Dec 31 2021 | ₪830k | ₪830k | ₪7m |
| Sep 30 2021 | n/a | n/a | ₪5m |
| Jun 30 2021 | n/a | n/a | ₪9m |
| Mar 31 2021 | n/a | n/a | ₪10m |
| Dec 31 2020 | ₪828k | ₪828k | ₪11m |
| Sep 30 2020 | n/a | n/a | ₪7m |
| Jun 30 2020 | n/a | n/a | ₪5m |
| Mar 31 2020 | n/a | n/a | ₪4m |
| Dec 31 2019 | ₪832k | ₪832k | ₪3m |
| Sep 30 2019 | n/a | n/a | ₪6m |
| Jun 30 2019 | n/a | n/a | ₪5m |
| Mar 31 2019 | n/a | n/a | ₪7m |
| Dec 31 2018 | ₪801k | ₪801k | ₪8m |
| Sep 30 2018 | n/a | n/a | ₪246k |
| Jun 30 2018 | n/a | n/a | -₪8m |
| Mar 31 2018 | n/a | n/a | -₪11m |
| Dec 31 2017 | ₪795k | ₪795k | -₪21m |
Compensation vs Market: Mordechai's total compensation ($USD269.57K) is below average for companies of similar size in the IL market ($USD425.15K).
Compensation vs Earnings: Mordechai's compensation has been consistent with company performance over the past year.
CEO
Mordechai Elgrabli (80 yo)
9.6yrs
Tenure
₪1,013,000
Compensation
Mr. Mordechai Elgrabli has been the Chief Executive Officer of Rekah Pharmaceutical Industry Ltd since August 24, 1993 and its Director since August 24, 1993. Mr. Elgrabli is a Member of Presidium of Mofet...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 9.6yrs | ₪1.01m | 15.32% ₪ 25.9m | |
| Director of Industrial Division & Director | no data | ₪1.62m | 15.32% ₪ 25.9m | |
| Chief Executive Officer of Ophir Shalpharm | 7.5yrs | ₪920.00k | no data | |
| Chief Executive Officer - Fresh of Life Pharma Ltd. | 3.1yrs | ₪907.00k | no data | |
| Director of Operations | no data | ₪684.00k | no data | |
| Deputy CEO & Director of Business Development | 13.7yrs | no data | no data | |
| Chief Executive Officer of Ophir & Shalpharm Ltd | no data | ₪705.00k | 0.026% ₪ 44.4k |
8.5yrs
Average Tenure
67.5yo
Average Age
Experienced Management: REKA's management team is seasoned and experienced (8.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 31.3yrs | ₪1.01m | 15.32% ₪ 25.9m | |
| Director of Industrial Division & Director | 31.3yrs | ₪1.62m | 15.32% ₪ 25.9m | |
| Director | 9.6yrs | no data | no data | |
| Chairman | 9.6yrs | ₪400.00k | no data | |
| Independent External Director | 9.6yrs | no data | no data | |
| Independent External Director | 8yrs | no data | no data | |
| Independent External Director | 8yrs | no data | no data | |
| Director | less than a year | no data | no data |
9.6yrs
Average Tenure
67.5yo
Average Age
Experienced Board: REKA's board of directors are considered experienced (9.6 years average tenure).